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Clove essential oil (Syzigium aromaticum) has been proven as anti-inflammatory agent. Formulation in the
cream type O/W preparations was required to be utilized by the community. The aims of this research was to
determined activity of cream as anti-inflammatory with concentration variation of essential oil. Cream was made
by melting method with concentration variation of clove essential oil: 2.5%; 5%; 10%. The cream was evaluated
for anti-inflammatory activities by using animal test BALB/c strain of mice that previously has been induced
inflammation with crotton oil. The results showed that increasing concentrations of clove essential oils tended
to increase the thickness of skin folds, thickness of the epidermis, the number of inflammatory cells and the
number of cells with COX-2 expression. The optimal concentration of essential oils in cream type O/W as
anti-inflammatory was 2.5%.
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1. INTRODUCTION
Inflammation was a response to injury, penetration of infectious
compounds, antigens or cell damage that indicate the presence of
harm to the body or disease. Therefore this process was a body
defense response that will induce the body’s efforts in minimizing
tissue damage.12 The body’s defense mechanism was a complex
sequence such as dilatation of the arteria, capillaries and veins
with increased vascular permeability, fluid exudation including
plasma proteins as well as leukocyte movements to inflammation
sites to neutralize and eliminate harmful stimulus.1
In inflammation there was increasing activity of several
enzymes such as protein tyrosine kinase, protein kinase C, phos-
phodiesterase, phospholipase A2, lipoxygenases, and cyclooxy-
genase (COX). These enzymes are enzymes that play a role in
the activation of endothelial cells and some other important cells
that play an important role in the occurrence of inflammation.3
Long-lasting inflammation can cause some pathological condi-
tions such as bacterial sepsis, rheumatoid arthritis and inflam-
mation of the skin. Skin inflammation can be demonstrated by
increasing of skin thickness, which may indicate an increase in
vascular permeability, edema, and swelling to the dermis layer
and proliferation of epidermal keratinocytes.4
Clove essential oil (Syzygium aromaticum) contains eugenol
which has activity as anti-inflammatory, local anaestetic,
analgetic, antibacteria, antioxidant, antihalitosis, aphrodisiac.5–9
∗Author to whom correspondence should be addressed.
The clove essential oil was included in the Myrtaceae fam-
ily with the largest component was eugenol of 70–96%.61011
The previous study showed the mechanism of eugenol (4-allyl-
2-methoxyphenol as an antioxidant and anti-inflammatory by
inhibits prostaglandin synthesis and neutrophil chemotaxis.12
The other study showed the mechanism of eugenol as anti-
inflammatory was by inhibiting the synthesis of prostaglandins
and neutrohil chemotaxis,812 inhibiting the NF-kB factor
that will activate tumor factor factor- (TNF- tumor
necrosis factor,1314 inhibited the expression of cyclooxyge-
nase (COX)-2 in macrophage-stimulated lipopolysaccharide
(LPS)15 and reduced production leucotrienes as mediataor
inflammataion.5
Based on the potential of eugenol in clove essential oil as
anti-inflammatory, it was necessary to develop the appropriate
dosage form. Inflammatory processes can occur in the skin.
This was because the skin was the first barrier of the body
to the environment, the first protector in case of damage and
trauma due to pathogen.3 Delivery through the skin was an
alternative drug delivery system that can provide benefits to
prevent first pass effects and gastric irritation.15 It has been
investigated in green tea delivery systems.16 Some nonsteroidal
anti-inflammatory drugs have been also formulated in topical
preparations to avoid systemic effects such as disorders gastroin-
testinal, cardiac and toxicity of the kidneys.17
The formulation of cream from herbal as anti-inflammatory
was done by the other researcher.1819 In this study clove essential
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oil will be formulated into O/W cream dosage form with various
concentrations. Cream was a semi-solid preparation that has soft
consistency and widely was used in cosmetics. Cream contains a
lot of water that gives a sense of cold, which can reduce the heat
that occurs in inflammation. Water also serves as an enhancer,
which can increase the permeability of the drug through the skin
without causing irritation or permanent damage to the skin’s sur-
face structure.20
The optimal concentration of clove essential oil in O/W cream
in this study will be determined by performing a series of tests
on the anti-inflammatory properties in vivo. The parameters that
was used to evaluate anti-inflammatory activity are the epidermal
thickness, the number of inflammatory cells and the number of
cells with COX-2 expression. This study was expected to pro-
duce topical pharmaceutical preparations of O/W cream that was
effective as anti-inflammatory.
2. MATERIAL AND METHOD
2.1. Material
Materials in this research were clove essential oil from UII and
ingredients of the cream with pharmaceutical degree obtained
from Bratacho Chem (vaseline, nipagin, nipasol, stearic alcohol,
na lauryl sulphate, propylene glycol and water). Test animals
used adult male mice, BALB/c strains (25–30 g) from the Inte-
grated Research and Testing Laboratory (LPPT), UGM.
2.2. Tools
Tools in this research were glassware and Olympus microscope.
All of the research procedures have obtained the ethical
approval letter from the Research Ethics mm ttee nu be ed
011508062 in 2015.
2.3. Preparation of Cream Formulation
Cream of clove essential oil was made with reference to the
results of previous research as presented in Table I.21 Cream was
made by melting method which beguns by melting the oil-soluble
material (mixture 1), i.e., vaseline, nipagin, alcohol stearate, on
waterbath at 75 C. Meanwhile for water-soluble ingredients
(mixture 2) also melted at the same temperature in different con-
tainers, i.e., nipasol, na lauryl sulfate and propylene glycol on
waterbath. Then the two mixtures were mixed on a warm mortar
and stirred until homogeneous. Finally clove essential oil was
added in the cream in a cold temperature.
2.4. Anti-Inflammatory Test
This study used 7 treatment groups, each consisting of 6 mice.
The seven groups included the normal control group and 6 groups
Table I. Formula of cream clove essential oil.
Ingredients Amount
Clove essential oil 2.5%, 5%, 10%
Vaseline 25
Nipagin 0.025
Nipasol 0.015
Stearic alcohol 25
Na lauryl sulphate 1
Propilen glycol 12
Aquades Ad 100
that was given inflammatory induction with croton oil. After
induction of inflammation each of groups received cream base
treatment (base control), the anti-inflammatory cream from mar-
ket (positive control), 2.5% concentration clove essential oil in
cream (F1), 5% concentration clove essential oil in cream (F2),
10% concentration clove essential oil in cream (F3), non-treated
group (negative control), respectively.
The procedure of induction were firstly the back of mice was
shaved. After 24 hours, the back of mice was dropped with 0.1 ml
of croton oil (4%) and then after 30 minutes was applied the
cream base, the anti-inflammatory cream from market (positive
control), 2.5% concentration clove essential oil in cream (F1), 5%
concentration clove essential oil in cream (F2) and 10% concen-
tration clove essential oil in cream (F3) as much as 100 mg daily
for 3 days. Furthermore, mice were sacrificed with cervical dis-
locations. The skin tissue is then removed and immersed in 10%
formalin for the preparation of histopathologic preparations with
hematoxylin eosin (HE) and COX-2 immunohistochemistry per-
formed according to standard methods in Pathology Laboratory,
Faculty of Medicine, UGM and Anatomical Pathology Labora-
tory, RS. Dr. Sardjito, Yogyakarta.21
The amount of inflammatory cell counts was performed on
histopathologic preparations painted with HE. Number of inflam-
matory cells was calculated on three planes view in each slice of
skin tissue per animal test. Calculation of inflammatory cells can
be known in the presence of blackish brown spots. The thick-
ness of epidermis was measured by the average distance between
the deepest epidermis layers and the outermost measured from
the three field view in each slice of skin tissue per animal test.
The number of cells expressing COX-2 was done by 400× mag-
nification on three viewing planes in each slice of skin tissue
per animal test, based on the number of cells showing the brown
color on the cytoplasm or its core. Calculations are performed
after skin tissue preparations are given immunohistochemical
staining using COX-2 polyclonal antibodies. Microscopic obser-
vations and measurements were done using a microscope that
has been connected with optilab.
3. RESULTS AND DISCUSSION
In this study data were gotten from macroscopic observation
parameter based on the thickness of skin fold (Fig. 1) and micro-
scopic observation parameters based on epidermal thickness,
the amount of inflammation cell and cell number with COX-2
expression (Table II) (Fig. 2). The results of statistical analysis
from data of thickness of skin fold showed significant difference
Fig. 1. Thickness skin fold of each groups.
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Table II. The results of the epidermal thickness, the number of inflam-
matory cells and the number of cells with COX-2 expression at various
treatments (N = 6).
The number of The number of
Epidermis inflammatory cells with
Group thickness (m) cells COX-2 expression
Normal control 34,70±59 2507±98 1,08±0,69
Negative control 78,78±10 3790±87∗ 2,45±0,51∗
Positive control 71,97±17 1423±51 1,93±0,35
Base control 145,638±42 2303±62 2,92±0,18
F1 128,293±12@& 2098±88#+ 1,66±0,60@
F2 143,257±29@& 2441±73# 2,22±0,56@
F3 118,132±22@& 3217±81#@ 2,42±0,36@
Information: ∗Significant difference with normal control, #significant difference with nega-
tive control, @significant difference with normal control, &significant difference with posi-
tive control, +significant difference with F2 and F3.
between normal control and negative control. This means induc-
tion with crotton oil has led to increase skin folds. The results
of the microscopic parameters was similar with the macroscopic
parameter. Data show that the thickness of the epidermis, the
amount of inflammatory cells and the number of cells with
Inflammatory cell
Cell with COX-2
expression
Epidermal thickness
Fig. 2. The microscopic picture of epidermal thickness, inflammatory cells
and cells with COX-2 expression at 400× magnification.
COX-2 expression in normal control was less than negative con-
trol. Significant differences were seen in data the number of
inflammatory cells and number of cells with COX-2 expression.
Its means that induction with crotton oil caused inflammation.
Croton oil was known to have irritant and inflammation prop-
erties so the oil was selected as an inflammatory inductor.22
Croton oil has a mechanism to activate the phospholipase A2
which then removes arachidonic acid from the cell membrane.
These arachidonic acids are then metabolized to prostaglandins
and leukotriene.23
Normal control (No treated), Negative control (treatment with
crotton oil 4%), Positive control (treatment with crotton oil 4%
and then cream anti-inflammatory from market), Base control
(treatment with crotton oil 4% and then base cream), F1 (treat-
ment with crotton oil 4% and then F1), F2 (treatment with crot-
ton oil 4% and then F2), F3 (treatment with crotton oil 4% and
then F3).
The positive control (antiinflammatory preparations from the
market) can decrease the thickness of skin fold that most closely
to normal controls. It was similar with microscopic parame-
ters especially data of epidermis thickness and the number of
inflammatory cells. The active ingredient in positive control
was diclofenac sodium. Diclofenac commonly was used as top-
ical anti-inflammatory. The mechanism of diclofenac was by
inhibitting of activity of cyclooxygenase-1 and cyclooxygenase-2
enzyme, thromboxane-prostanoid receptor that influenced to
release and up take of arachidonic-acid, lipooxigenase enzyme
and activating of oxide-cyclic guanosine monophosphate path-
way. Topical diclofenac dosage forms was more effective than
the other non-steroidal anti-inflammatory drug.2425
Base control group was used to evaluate the potential of the
cream base as anti-inflammatory. Treatment with cream base was
also able to reduce the thickness of skin fold and the number of
inflammatory cells. It means the ingredients in base have the anti-
inflammatory activity. On the other hand the epidermal thickness
and the number of cells with COX-2 expression of base control
was higher than negative control. It was needed the other data
from next research to support the possibility of ingredients in
base as anti-inflammatory.
The cream with 2.5% concentration of clove essential oil can
reduce the thickness of skin fold higher than the others concen-
tration. It was similar with data of the number of inflammatory
cells and the number of cells with COX-2 expression. This activ-
ity could reduce the number of inflammatory cells so there was
significant difference with negative control. The activity of cream
with 2.5% concentration of clove essential oil at the paramter of
the number of inflammatory cells was significant difference with
the F2 (5% concentration of clove essential oil) and F3 (10% con-
centration of clove essential oil). It meaned that this concentration
has the best activity as the anti-inflamamtory based on the data
of the number of inflammatory cells. However there was signifi-
cant different with normal control in data of epidermis thickness
and the number of cells with COX-2 expression and positive con-
trol in data of epidermis thickness. The activity of cream with
2.5% clove essential oil concentration has not been able to restore
the inflamed skin to normal condition. This activity was also still
smaller than the anti-inflammatory dosage forms on the market
based on data epidermis thickness. The significant difference with
normal control and positive control also occur in F2 and F3.
The treatment with cream type O/W with variation con-
centrations of clove essential oil can reduce the number of
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inflammatory cells (there was significant difference) and the
number of cells with COX-2 expression (there was not signifi-
cant difference) when was compared with the negative control.
It showed eugenol in essential oil of clove has potential as anti-
inflammatory. Mechanism action of eugenol in the clove essential
oil as an antioxidant and anti-inflammatory was by inhibition of
prostaglandin synthesis and neutrophil chemotaxis.812 In addi-
tion, it has been proven that the phenolic antioxidants can inhibit
the expression of cyclooxygenase (COX)-2 in lipopolysaccha-
ride (LPS) stimulated makrofag8 and can inhibit the activity of
factor-kB in activating TNF-. Its as agents involved in the pro-
cess of inflammation and carcinogenesis in various processes
pathophysiology,13 transcription factors that are important in reg-
ulating inflammatory response and expression of inflammatory
cytokines and stimulate cells activity in smooth muscle which
has a major role in designing the inflammatory process. On the
other hand, COX as an enzyme converts arachidonic acid into
prostanoid. There are two isoforms of COX, namely COX-1 as
constitutive that resides in most types of cells, and COX-2, which
appears as growth factors, cytokines and LPS through the activa-
tion of transcription factors such as NF-kB in various cells.14
However the decreasing of the number of inflammatory cells
and the number of cells with COX-2 expression have not pro-
vided the same conditions with normal control because there
were significant differences. Except for data on the number of
inflammatory cells in which the treatment group with concen-
trations of 2.5% and 5% had a smaller number of inflammatory
cells compared with normal control. The activity was not same
with activity of Na Diclofenac, which was active ingredient in
the anti-inflammatory cream from market. In all three parame-
ters the treatment group with cream still has higher an epidermal
thickness, the number of inflammatory cells and the number of
cells with COX-2 expression than the positive control.
The increasing concentration of essential oils in cream raised
epidermal thickness, the number of inflammatory cells and
the number of cells with COX-2 expression significantly. The
increasing of the number of inflammatory cell at the F3 (10%
concentration of clove essential oil) gived significant difference
with normal control. This was probably due to the activity of
eugenol as active compound in clove essential oil as enhancer.26
Essential oil could be used as enhancer.27 Essential oil con-
tains terpenes that can be used as enhancers.2829 It was because
of their high ability to improve penetration with a skin irri-
tant effect and low systemic toxicity at low concentrations of
1–5%. Terpen works by altering the fat structure of the stratum
corneum thus increasing the polar drug’s diffusion coefficient in
the membrane.30 One of the enhancer mechanisms by damaging
the lipid tissue may cause a certain concentration to cause side
effects on the skin.31 Essential oil as enhancer did not cause skin
toxicity but some times caused mild irritation.32
4. CONCLUSION
The optimum concentration of clove essential oil in cream type
O/W as anti-inflammatory was 2.5%.
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